- New type of supernova detected as black hole causes star to explode Reuters
- Star Trying to Swallow a Black Hole May Have Triggered a New Type of Supernova ScienceAlert
- Why the death of this star is very, very strange The Washington Post
- A peculiar supernova prompts new theories about the cosmos USA Today
- How AI is changing the way we discover cosmic events The Indian Express
Blog
-
New type of supernova detected as black hole causes star to explode – Reuters
-
How to customize your Google Search results to see your favorite sites first
What are Top Stories in Google Search?
Google Top Stories is a section on the Google Search results page that highlights the most relevant and timely news articles related to your search. It appears as a carousel at the top of the page when Google detects a current event, trending topic, or news query.
Also: Google’s new Search mode puts classic results back on top – how to access it
Is there a quick way to add ZDNET as a preferred source?
Yes. In Chrome and Chromium browsers specifcally, you can go to this link to automatically load ZDNET as a preferred source.
Elyse Betters Picaro / ZDNET Will I only see ZDNET in Top Stories once I add it?
No. Google will still show a mix of sources, but you’ll see ZDNET articles more often when they’re relevant and fresh.
Can I change my preferred sources later?
Yes. Your preferences aren’t set in stone. If you ever want to add more sources or remove one, you can go back to the star button next to Top Stories and make any changes.
Can I add more than one preferred source?
Yes. You can add as many as you like — Google says over half of early testers chose four or more.
Do I need a Google Account to set preferred sources?
Yes. You’ll need to be signed in to your Google Account so your preferences are saved.
I can’t set a preferred source on Google. Why?
As of August 2025, Preferred Sources is only rolling out in English in the US and India, but that may expand in the future.
Get the morning’s top stories in your inbox each day with our Tech Today newsletter.
Continue Reading
-
Megadeth Announce Final Album and Farewell Tour
Megadeth founder and frontman Dave Mustaine has announced that the long-running metal band’s forthcoming album and 2026 tour will be their last.
The announcement, in a social post directly shared with his fans and “Cyber Army,” features the band’s mascot and Mustaine’s “alter ego” Vic Rattlehead “speaking” for the first time.
However, the statement is from Mustaine himself. “There’s so many musicians that have come to the end of their career, whether accidental or intentional,” he says. “Most of them don’t get to go out on their own terms on top, and that’s where I’m at in my life right now. I have traveled the world and have made millions upon millions of fans and the hardest part of all of this is saying goodbye to them.
“We can’t wait for you to hear this album and see us on tour. If there was ever a perfect time for us to put out a new album, it’s now,” he continues. “If there was ever a perfect time to tour the world, it’s now. This is also a perfect time for us to tell you that it’s our last studio album. We’ve made a lot of friends over the years and I hope to see all of you on our global farewell tour. Don’t be mad, don’t be sad, be happy for us all, come celebrate with me these next few years.
“We have done something together that’s truly wonderful and will probably never happen again,” he concludes. “We started a musical style, we started a revolution, we changed the guitar world and how it’s played, and we changed the world. The bands I played in have influenced the world. I love you all for it. Thank you for everything.”
Megadeth was founded in 1983 after the famously irascible Mustaine was ejected from Metallica, the pioneering metal band he co-founded (co-writing four of the ten songs on the band’s iconic debut, “Kill ‘Em All,” including the classics “Jump in the Fire” and “The Four Horsemen”). Megadeth released their debut in 1985 and truly arrived with the following year’s album “Peace Sells… but Who’s Buying?,” revealing a punk-influenced political attitude that has remained with the group ever since.
Mustaine, his trademark snarling vocals and scorching guitar work are the only constants across the band’s history, which has included 16 studio albums — five of them certified platinum in the U.S. — multiple lineup shifts, at least seven record labels, a cancer diagnosis, substance abuse and recovery, the controversial 2021 departure of founding bassist Dave “Junior” Ellefson, a prominent role in Penelope Spheeris’ era-defining 1988 documentary “The Decline of Western Civilization Part II: The Metal Years,” and countless blown eardrums and strained neck muscles.
Along with Metallica, Slayer and Anthrax, Megadeth is widely recognized as a member of the “Big Four” Mount Rushmore of thrash metal, a status that was more or less codified with the 1990-91 “Clash of the Titans” tours of North America and Europe. Megadeth and Slayer headlined those tours and were joined by a shifting lineup that included Anthrax, Suicidal Tendencies, Testament and others. Metallica remain one of the world’s biggest rock bands; Slayer officially disbanded in 2019 but have reunited for several concerts beginning in 2024; Anthrax have undergone many personnel shifts but are currently active with 4/5 of their classic lineup.
Megadeth’s lineup currently currently comprises Mustaine with Brooklyn-born bassist James LoMenzo, Finnish guitarist Teemu Mäntysaari and Belgian drummer Dirk Verbeuren. Thursday’s announcement included the cover artwork for the band’s final album (below) but not the title.
Continue Reading
-
Breakthrough T1D-Authored Paper Paves the Way for Beta Cell Replacement Therapies on the Path to Cures for Type 1 Diabetes
Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits
NEW YORK, Aug. 14, 2025 /PRNewswire/ — Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, announced the publication of a paper in the journal Diabetes that serves as a roadmap for beta cell replacement therapies that can cure type 1 diabetes. The paper, “Future Directions and Clinical Trial Considerations for Novel Islet β-Cell Replacement Therapies for Type 1 Diabetes”, was authored by a team of Breakthrough T1D leaders and staff, including Sanjoy Dutta, Ph.D., Chief Scientific Officer, Esther Latres, Ph.D., Vice President of Research, and Marjana Marinac, Pharm.D., Associate Vice President of Regulatory Affairs, along with other leaders in the field. The paper provides guidelines that the entire T1D field can follow to accelerate the availability of next-generation beta cell replacement therapies for people with T1D by designing clinical trials that speed their development, regulatory approval, access, and adoption.
Decades of research have demonstrated that beta cell replacement therapies can be effective and, in some cases, have resulted in insulin independence for individuals with T1D. However, currently available beta cell replacement therapies are limited to people with T1D who have unstable blood sugar management and severe hypoglycemia and require the use of medicines that broadly suppress the immune system to protect the cells.
The daily burden of T1D is substantial for everyone living with the condition, and the paper emphasizes the need for innovative clinical trial design for cell therapies that broadens eligibility criteria so that more people with T1D can participate and experience the potential benefits. It also outlines the importance of expanding the current outcomes used to determine the effectiveness of cell therapies in clinical trials to include patient-reported outcomes and continuous glucose monitor metrics, such as when a participant’s blood sugars are in the target range.
“Clinical trials to support the development of islet cell replacement therapies need to evolve to include a broader representation of people living with type 1 diabetes who could benefit from these novel therapies,” said Marjana Marinac. “This includes expanding the outcomes used to assess the benefits of cell replacement that reflect how people with T1D feel and function.”
“There are still significant unmet needs in the type 1 diabetes community. Breakthrough T1D’s roadmap is supported by the assessment of clinically meaningful outcomes and driving research toward solutions that address key factors such as cell sources and protection strategies that will broaden the people with T1D who could benefit from emerging cell replacement therapies,” said Esther Latres.
The paper’s focus on the pathway for future cell therapy research aligns with Breakthrough T1D’s mission priorities and Project ACT, the organization’s initiative to make curative cell therapies for T1D a reality.
About Breakthrough T1D (formerly JDRF)
As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition.About type 1 diabetes (T1D)
T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.Contact:
Casey Fielder
509-651-0087
[email protected]SOURCE Breakthrough T1D, Formerly JDRF
Continue Reading
-
Scientists Use Climate Data To Map, Predict Amphibian Chytrid Disease
Researchers may have a new tool in the fight to protect neotropical frogs from extinction, thanks to climate data. In a recently published study in the journal Diversity and Distributions, researchers from the Smithsonian’s National Zoo and Conservation Biology Institute (NZCBI) and the Smithsonian Tropical Research Institute (STRI) created a high-resolution map of Panama showing how a deadly amphibian disease moved across Panama over a 13-year period. But the data also provides insight into where the disease is the most dangerous and shows regions that may be havens for reintroduced, captive-bred frogs.
Since its first scientific description in 2000, Batrachochytrium dendrobatidis (Bd), a fungus that causes the deadly amphibian chytrid disease, has devastated amphibian populations in Central and South America. Believed to have originated in Asia, chytrid has since spread to many parts of the world, and the disease is responsible for wiping out nine frog species in Panama alone.
Like other fungi, chytrid requires a cool, wet environment to thrive. In chytrid-friendly conditions, disease outbreaks can decimate frog populations. But scientists have found that the fungus cannot thrive when the temperature is too high or the air is too dry. While the disease has spread throughout mainland Panama, the team wondered if the climate parameters might create an opportunity to find pockets where chytrid was less likely to kill.
By pairing satellite data with 13 years’ worth of atmospheric modeling, researchers created an ultra-high-resolution, daily temperature and humidity map for the nation. They paired this with a second dataset of over 4,900 disease samples taken from 314 sites across Panama. The second dataset tracked the amount of fungus present on each frog, known as the fungal load, over 13 years. When overlaid, the two data sets provided a clear picture of when and where the chytrid disease was the most intense. Higher elevations consistently remained more hospitable to the fungus, but rainy seasons brought chytrid-friendly conditions to the lowlands and led to waves of outbreaks.
“By compiling the hard-earned data from many amphibian researchers, we have been able to draw an unprecedented, detailed picture of the intensity of Bd in Panama through time and space,” said Carrie Lewis, doctoral student at George Mason University’s Department of Geography and Geoinformation Science, who led the study. “My hope is that we can use this detailed information to inform conservation actions in a more refined way.”
Although chytrid disease has devastated amphibian populations, the presence of the chytrid fungus alone is not a death sentence. Recognizing this, the research team built three models: one showing fungal presence; a second at “medium intensity,” which researchers consider an indicator of a serious infection; and a third at “high intensity,” which researchers associated with significant disease outbreaks. Researchers found that by examining the weather conditions 15 days prior to sampling, they could predict the presence and intensity of the chytrid fungus.
By mapping out the path and intensity of chytrid, it became clear that the disease thrives in mountainous regions, which tend to remain cooler and more humid than lowland areas. With this knowledge, researchers may be able to identify climatic refuges—areas less suitable for the chytrid disease where frogs may have a fighting chance against the fungus.
“The ability to identify places where frogs might be able to survive chytrid is critical for two reasons,” said Brian Gratwicke, NZCBI biologist and senior author of the study. “One, it allows us to look for frogs in those areas who might have developed resistance to the fungus. Two, those same areas might be sites where we can return captive-bred frogs into the wild. Both aspects could be significant turning points in the fight against the chytrid disease.”
Since 2009, the Panama Amphibian Rescue and Conservation Project based in Gamboa, Panama, has bred 12 species of frogs, all of which are facing extinction. After years of successful breeding, there are now enough animals to begin rewilding efforts. As researchers work toward reintroduction trials for imperiled Panamanian species, these prediction models will be crucial to determining when and where trials should take place.
This collaboration between 18 coauthors was partially supported with funding from the National Science Foundation, the German Science Foundation and the Bezos Earth Fund through the Tropical Amphibian Research Initiative.
Smithsonian’s National Zoo and Conservation Biology Institute (NZCBI)
NZCBI leads the Smithsonian’s global effort to save species, better understand ecosystems and train future generations of conservationists. Its two campuses are home to more than 2,200 animals, including some of the world’s most critically endangered species. Always free of charge, the Zoo’s 163-acre park in the heart of Washington, D.C., features animals representing 400 species and is a popular destination for children and families. At the Conservation Biology Institute’s 3,200-acre campus in Virginia, breeding and veterinary research on nearly 250 animals representing 20 species provide critical data for the management of animals in human care and valuable insights for conservation of wild populations. NZCBI’s 305 staff and scientists work in Washington, D.C., Virginia and with partners at field sites across the United States and in more than 30 countries to save wildlife, collaborate with communities and conserve native habitats. NZCBI is a long-standing accredited member of the Association of Zoos and Aquariums.Smithsonian Tropical Research Institute (STRI)
Headquartered in Panama City, Panama, STRI is a unit of the Smithsonian Institution. Our mission is to understand tropical biodiversity and its importance to human welfare, to train students to conduct research in the tropics and promote conservation by increasing public awareness of the beauty and importance of tropical ecosystems. Visit the institute at our website and on Facebook, X and Instagram for updates.# # #
SI-173-2025
Continue Reading
-
Cristiano Ronaldo spends £270k on gifts for Georgina Rodriguez after engagement is confirmed
- Ronaldo spends £270K on engagement presents
- Popped the question earlier this week
- Gifts include car and watch
Follow GOAL on WhatsApp! 🟢📱 Continue Reading
-
M4 Ultra Mac Pro rumor processor codenamed hidra
New code accidentally leaked by Apple suggests it is still hard at work on a new Mac Pro powered by the M4 Ultra chip.
Apple’s premium desktop machine is currently powered by the aging M2 Ultra chip with a 24-core CPU and a 60-core GPU. That’s backed up by a 32-core Neural Engine.
Now, code discovered by Macworld hints at the possible arrival of a new M4 Ultra version of the machine. If accurate, this could be the first Mac to use an M4 Ultra chip.
The new Mac Pro has an internal identifier of t8152. It also matches the previously known Hidra codename.
Apple’s Mac Pro isn’t updated very frequently. The M4 Ultra chip would replace the M2 Ultra version of the Mac Pro that is on sale as of August 14, 2025.
While we don’t know for sure what the M4 Ultra will have in terms of core counts, it’s likely to sport 32 CPU cores and an 80-core GPU. That’s assuming, as expected, that it’s based on the silicon already available in the M4 Max MacBook Pro and M4 Max Mac Studio.
While this code leak does suggest that Apple is still tinkering with an M4 Ultra-powered Mac Pro, it doesn’t mean it will ever see the light of day. Apple tests tons of devices, there are frequently code snippets left behind, and not all of the leaked devices find their way into an Apple Store.
That being said, there is little doubt that the Mac Pro is overdue for an update. The current model debuted in 2023, and it seems unlikely Apple would skip both the M3 and M4 families of chips without refreshing its towered Mac.
The wildcard here is the M5 chips, likely to be released in the fall of 2025. M5 chip identifiers recently appeared in iOS 18 code, so it’s likely that Apple’s next-gen chips aren’t all that far from release.
Continue Reading
-
Franco Mastantuono’s Surprising Real Madrid Shirt Number Confirmed
Real Madrid confirmed Franco Mastantuono will inherit Gonzalo García’s No. 30 shirt, the same number the Argentine donned at River Plate.
Despite signing with Los Blancos back in June, Mastantuono had to wait until his 18th birthday to be officially presented at Real Madrid City. The forward started his time off in the Spanish capital with a medical and then gave his first remarks as a Real Madrid player before revealing his new shirt.
Although Mastantuono was expected to take the number 25, which is the last first-team squad number available ahead of the 2025–26 season, the teenager instead claimed 30.
Leaving the number 25 open gives Real Madrid the opportunity to sign one more player during the summer transfer window to round out their first-team squad. The club has been in the market for a midfield reinforcement, most recently linked with Manchester City’s Rodri and Crystal Palace’s Adam Wharton.
M A S T A N T U O N O 🤝 3️⃣0️⃣#WelcomeMastantuono | @adidasfootball pic.twitter.com/uePSfyL1zf
— Real Madrid C.F. 🇬🇧🇺🇸 (@realmadriden) August 14, 2025
The decision also means Mastantuono is technically registered as a Real Madrid Castilla player. Real Madrid took a similar approach when Vinícius Júnior and Rodrygo joined the team as teenagers.
The good news for Real Madrid is that they can still have Mastantuono with the first team all season long. Since the Argentine is under 23 years old, La Liga regulations allow the new signing to feature for the first team without needing a number change, even if he crosses the 10-match threshold that usually demands a player take a number no higher than 25.
The scenario benefits all parties involved, especially since Mastantuono already has ties to the number 30.
“It was me who asked president Florentino [Pérez] to take number 30,” he said. “It’s a special number for me. I wore it at River Plate too.
“It’s a very special day for me. It’s a dream come true as a footballer and as a person, to join a club like Real Madrid, the biggest in the world. I’m thrilled, and I want to share that joy with you because this will be a day I will remember forever.
“I promise I will give my life to this jersey, it’s the dream I have always had.”
READ THE LATEST REAL MADRID NEWS, TRANSFER RUMORS AND MORE
Continue Reading
-
FDA Grants Fast Track Designation to HLD-0915 for Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer |
Image credit: © pikovit – stock.adobe.com
The FDA has granted fast track designation to HLD-0915 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).1
HLD-0915 is currently under investigation in a first-in-human, phase 1/2 trial (NCT06800313) in patients with mCRPC. The open-label, multi-center trial is designed to ascertain the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of HLD-0915 monotherapy in patients with mCRPC.
The study’s phase 1 dose escalation will explore the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion of HLD-0915 as a single agent. Subsequent phase 2 expansion cohorts will further characterize the safety and efficacy of HLD-0915.
“We are pleased HLD-0915 has been granted fast track designation by the FDA for patients with mCRPC,” Christian Schade, president and chief executive officer of Halda Therapeutics, stated in a news release. “Fast track designation is an important step forward as we work to advance this program through clinical development and, ultimately, to bring a novel, highly selective, oral-based treatment option to patients living with this challenging disease.”
HLD-0915 is an orally administered, bifunctional small molecule therapy designed to selectively target prostate cancer tumor cells by binding the androgen receptor and effector proteins. The ternary complex stimulates the formation of new protein-protein interactions, preventing an essential function within cancer cells that translates antitumor activity.
In preclinical prostate cancer models, treatment with HLD-0915 led to tumor shrinkage and reductions in prostate-specific antigen (PSA), with favorable therapeutic index, including in drug-resistant models.
The ongoing phase 1/2 trial will seek to further define the therapeutic profile of the agent. Eligible patients must be at least 18 years of age and have received a histological, pathological, and/or cytological diagnosis of prostate adenocarcinoma.2 Additional eligibility criteria stipulate that patients must have undergone prior orchiectomy and/or ongoing androgen deprivation therapy and have a castrate level of serum testosterone.
Progression on prior therapy, defined by PSA progression with or without radiographic progression, is also mandated. Traditional enrollment criteria, including an ECOG performance status of 0 or 1, life expectancy of at least 3 months, and adequate hematological, renal, and hepatic function, are also required. Notably, patients must have the ability to swallow an oral medication, given HLD-0915’s administration. Patients who are receiving a stable dose of bisphosphonate or denosumab for 30 days prior to enrollment are included.
Patients whose tumors express a neuroendocrine or small cell carcinoma component on histopathology will be excluded. Patients will also be prohibited from accrual if they have experienced a recent major bleed or have a known bleeding disorder, are receiving continuous corticosteroids at a prednisone-equivalent dose of greater than 10 mg/day, or have received systemic anticancer therapy or other investigational drugs within 2 weeks before the first dose of HLD-0915.
Approximately 33 patients will receive HLD-0915 in 21-day treatment cycles until evidence of disease progression or study discontinuation.
The primary objective of phase 1 is to establish the frequency of dose-limiting toxicities and adverse effects. Secondary objectives of phase 1 include the evaluation of PK parameters, the proportion of patients with PSA declines measuring at least 30%, 50%, and 90%, and clinical end points like objective response rate, duration of response, radiographic progression-free survival, and time to response.
In February 2025, Halda Therapeutics announced that the first patient had been dosed in the trial.3
“We are very pleased to have initiated the clinical evaluation of HLD-0915 to address the unmet needs of cancer patients with mCRPC,” Schade stated at the time of the announcement. “Initiation of this study marks a significant step in advancing our novel small molecule RIPTAC [Regulated Induced Proximity TArgeting Chimeras] modality as an important new approach for the treatment of cancer.”
References
- Halda Therapeutics receives FDA fast track designation for HLD-0915 for the treatment of metastatic castration-resistant prostate cancer. News release. Halda Therapeutics. August 14, 2025. Accessed August 14, 2025. https://haldatx.com/halda-therapeutics-receives-fda-fast-track-designation-for-hld-0915-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer/
- A study of HLD-0915 in patients with metastatic castration resistant prostate cancer (mCRPC). ClinicalTrials.gov. Updated April 16, 2025. Accessed August 14, 2025. https://clinicaltrials.gov/study/NCT06800313
- Halda Therapeutics announces first patient dosed in phase 1/2 clinical trial evaluating HLD-0915 in metastatic castration-resistant prostate cancer. News release. Halda Therapeutics. February 24, 2025. Accessed August 14, 2025. https://haldatx.com/halda-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-evaluating-hld-0915-in-metastatic-castration-resistant-prostate-cancer/
Continue Reading
-
Taylor Swift, Travis Kelce share rare kiss on New Heights podcast
Taylor Swift made headlines with a rare, unfiltered interview on New Heights, the podcast hosted by her boyfriend, Travis Kelce, and his brother Jason Kelce. Over the two-hour episode, Swift not only revealed details about her much-anticipated 12th studio album The Life of a Showgirl but also shared personal stories about her romance with Kansas City Chiefs tight end. The couple ended the interview with a light-hearted, on-air kiss: much to Jason’s amusement. According to E! Online, reacting to the moment, Jason exclaimed, “Oh my gosh, alright.” After which, the singer was seen getting shy.
Taylor Swift and Travis Kelce on the New Heights podcast.(YouTube/New Heights) How the podcast sparked a romance between Taylor Swift and Travis Kelce
On the latest episode of the podcast, Swift credited the New Heights for bringing her together with Travis after he had famously mentioned making her a friendship bracelet and wanting to meet her during the Eras Tour, in a 2023 episode.
Swift, recalling the moment, said that her relatives insisted she meet Travis. She added, “It felt like something out of an 80s John Hughes movie…and it worked.” She called Kelce ‘the good kind of crazy’ and a ‘human exclamation point.’
New Album: Life Behind the Curtain
The podcast was not all about romance; Swift also announced the release date of her next album, The Life of a Showgirl. The album, created during her record-breaking Eras Tour, will be coming out on October 3. She said the album reflected everything that goes on behind the curtain of her public life. The cover art, featuring Swift in a bejewelled gown submerged in water, symbolises her quiet post-performance moments.
During the podcast, Swift said that she has been wanting to make an album like this for a very long time. The album, she said, is an upbeat, joyful, and wildly dramatic: a stark contrast to her previous album, The Tortured Poets Department. Pre-orders for the album crashed her website moments after the reveal.
Also read: ‘She’s been cooking’: First glimpses from Taylor Swift’s The Life of a Showgirl has the internet melting
Easter eggs, album rights, and personal triumphs
Swift talked about her unique ‘Easter eggs’ and noted they never reference her personal life properly, only her art, reported BBC. However, she did reminisce about her emotional triumph, stating that she was able to reclaim her first six albums and described it as a life-altering moment.
Love, football and sourdough bread
The couple shared light-hearted anecdotes of their life together, baking sourdough (complete with a few accidental cat hairs and a hint of Travis’ chest hair) and Swift’s rudimentary understanding of football. Travis complimented Swift for immersing herself into his world, whereas she noted that she appreciated his patience and how he led her along.
FAQs:
Q: When will Taylor Swift’s new album be released?
A: The Life of a Showgirl will be released on October 3.
Q: How did Taylor Swift and Travis Kelce meet?
A: Their connection began after Travis mentioned her on New Heights, sparking mutual interest and encouragement from friends and family.
Q: What makes this album different from her last?
A: Swift describes it as upbeat, joyful, and dramatic, in contrast to the introspective tone of The Tortured Poets Department.
Q: What are Easter eggs in Swift’s work?
A: Secret references or clues hidden in her music, videos, and performances for fans to decode.
Continue Reading